Temsirolimus in second or subsequent line in patients with metastatic renal cell carcinoma (mRCC): Better activity in good-intermediate prognosis patients.

G. Vitali,M. Duca,Clara Fugazza,S. Longoni,S. Trinca,Domenica Ceraulo,E Villa,M. Bregni

Temsirolimus in second or subsequent line in patients with metastatic renal cell carcinoma (mRCC): Better activity in good-intermediate prognosis patients.

2010

G. Vitali
M. Duca
Clara Fugazza
S. Longoni
S. Trinca
Domenica Ceraulo
E Villa
M. Bregni

e15081 Background: To evaluate the activity and safety of the inhibitor of mammalian target of rapamycin (mTOR) temsirolimus in unselected, pre-treated patients with mRCC. Methods: Eligible cases h...

Keywords:

Pathology
Temsirolimus
Renal cell carcinoma
Cancer research
Oncology
Internal medicine
Medicine
PI3K/AKT/mTOR pathway
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations